6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03575195 (ClinicalTrials.gov) | July 15, 2019 | 21/6/2018 | Microbiota Intervention to Change the Response of Parkinson's Disease | Microbiota Intervention to Change the Response of Parkinson's Disease | Parkinson Disease | Drug: Rifaximin;Other: Placebo | University of California, San Francisco | Nova Southeastern University;Gateway Institute for Brain Research | Recruiting | 30 Years | N/A | All | 86 | Phase 1;Phase 2 | United States |
2 | NCT03958708 (ClinicalTrials.gov) | May 13, 2019 | 14/5/2019 | Modulation of Gut Microbiota by Rifaximin in PD Patients | Modulation of Gut Microbiota by Rifaximin in PD Patients | Parkinson Disease;Inflammation | Drug: Rifaximin 550 MG | Taipei Medical University Shuang Ho Hospital | NULL | Recruiting | 45 Years | 70 Years | All | 20 | Phase 1;Phase 2 | Taiwan |
3 | NCT02470780 (ClinicalTrials.gov) | December 2015 | 4/6/2015 | Treating Bacterial Overgrowth in Parkinson's Disease | Treating Bacterial Overgrowth in Parkinson's Disease | Parkinson's Disease;Small Intestinal Bacterial Overgrowth | Drug: Rifaximin;Drug: Placebo | University of Cincinnati | NULL | Completed | 18 Years | N/A | All | 24 | Phase 2;Phase 3 | United States |
4 | NCT01662791 (ClinicalTrials.gov) | September 2012 | 7/8/2012 | Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth | Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth | Parkinson's Disease | Drug: Rifaximin | Mayo Clinic | NULL | Completed | 18 Years | N/A | All | 49 | Phase 3 | United States |